# Workflow 1.6.1 Mechanical Evidence Recheck

Fresh evidence_rechecker runtime ID: `01a128e9-7924-74c3-a02e-3056552798d7`. Model/effort/start: `gpt-6.1-sol/high/FRESH_SPAWN`. Exact stable-ID scope: C001. One of one assigned IDs and every affected location were checked. This records source facts and classification, with no human disposition.

The complete scope and review contract, current ledger, initial inclusion screen, original F-XS-001 and F-ST1-001 finding cards, source inventory and tooling record were read. Direct supplied PDFs are final authority. Direct local Poppler `pdftotext -layout` 26.01.0 independently read main PDF pp.3,4,5 and results PDF pp.22–24 to standard output. All four full-page current-source images under `screening/direct_source/` were visually inspected: `main-5.png`, `results-22.png`, `results-23.png`, `results-24.png`. Those images were generated from these supplied PDFs during this run with Poppler `pdftoppm` 26.01.0; their cited text was independently matched by direct-source extraction. No OCR/source disagreement, new render, OCR, fallback environment, scientific Python, external evidence or GPU was needed. No supplied source or reusable asset was modified. No additional derivative was written.

## C001 — DBP1 TG placebo subgroup population does not reconcile across report documents

**Status:** Pending Human Adjudication

**Finding IDs:** F-XS-001, F-ST1-001

**Review domain:** statistical_results

**Relationship type:** S_C

**All relationships:** S_C

**Compared document roles:** REPORT main article Table 1 p.5 versus REPORT results supplement eFigures 3P–3R pp.22–24; main article methods pp.3–4 are REPORT context.

**Evidence state:** reproduced

**Classification rationale:** Confirmed without correction. Table 1 describes participant characteristics observed in the trial, including genotypes. eFigures 3P–3R report trial relapse-or-death subgroup curves, hazard ratios and observed risk counts. Both are REPORT by content. The registered discrepancy is between two distinct REPORT documents, giving S_C. Its subject is participant counts rather than attribution of an outcome or time point, so statistical_results applies. The agreement of TT/GG categories within each document does not add S_W. No PLAN location is one of the conflicting counts; a plan identifying the genotype or intended subgroup would only corroborate context and would not add P_R or P_P. Since S_C is the only relationship, the precedence P_R > P_P > S_C > S_W selects S_C.

**Classification ambiguity:** None for the source roles, relationship or domain. The unresolved genotype-population definition is an evidence limitation, not an uncertain document role.

**Locations found, source values matched and comparator matched:** All named locations were found at the cited physical PDF pages, and each registered transcription matched the direct PDF text and relevant source-page image.

| Exact supplied-source location | Role by content | Independently read value or text | Source/comparator match |
|---|---|---|---|
| [Main PDF p.5, Table 1 continued, DBP1 TG row, placebo column](../../../jama_urashima_2019_oi_190023.pdf#page=5) | REPORT: observed participant characteristics | 57 (39), under No. (%) of Participants | Yes: registered source count 57 and percentage 39 match. |
| [Main PDF p.5, Table 1 continued, DBP1 TT and GG rows, placebo column](../../../jama_urashima_2019_oi_190023.pdf#page=5) | REPORT | TT 82 (55); GG 9 (6) | Yes: corroborating counts 82 and 9 match. |
| [Main PDF p.5, Table 1 continued, DBP1 TT/TG/GG rows, vitamin D column](../../../jama_urashima_2019_oi_190023.pdf#page=5) | REPORT | TT 134 (58); TG 87 (38); GG 10 (4) | Yes: all three reference-arm counts and percentages match. |
| [Results PDF p.23, eFigure 3Q, DBP1 TG, placebo No. at risk at 0 years](../../../joi190023supp2_prod.pdf#page=23) | REPORT: observed subgroup relapse-or-death analysis | Placebo 59; vitamin D 87; horizontal axis Years since Randomization; caption names prespecified DBP1 TG subgroup and relapse or death | Yes: comparator 59, matching genotype/allocation and zero-year location confirmed. |
| [Results PDF p.23, eFigure 3Q, estimate annotation](../../../joi190023supp2_prod.pdf#page=23) | REPORT | Hazard ratio 1.00 (95% CI 0.44 to 2.24); P = 0.99; P interaction = 0.49 | Yes: associated result matched; no incompatible inferential tuple is asserted by this candidate. |
| [Results PDF p.22, eFigure 3P, DBP1 TT, No. at risk at 0 years](../../../joi190023supp2_prod.pdf#page=22) | REPORT | Placebo 82; vitamin D 134; caption names DBP1 TT, relapse or death | Yes: both adjacent-category comparator counts match. |
| [Results PDF p.24, eFigure 3R, DBP1 GG, No. at risk at 0 years](../../../joi190023supp2_prod.pdf#page=24) | REPORT | Placebo 9; vitamin D 10; caption names DBP1 GG, relapse or death | Yes: both adjacent-category comparator counts match. |
| [Main PDF p.3, SNP Analyses and Statistical Analysis](../../../jama_urashima_2019_oi_190023.pdf#page=3) | REPORT: methods used for this trial | DBP1 rs7041; peripheral-blood DNA and direct sequencing; SNP subgroups prespecified; randomization-group efficacy analysis; Cox model for HR and 95% CI; baseline 25(OH)D missing-data/imputation statements | Yes: contextual methods found. They do not supply a genotype-specific population reconciliation. |
| [Main PDF p.4, continuation of methods and Study Population](../../../jama_urashima_2019_oi_190023.pdf#page=4) | REPORT | Imputation covariates continue from p.3; all 417 included in efficacy analyses; allocation 251/166 | Yes: supplementary contextual read confirms that the imputation sentence concerns 25(OH)D and that whole-trial efficacy counts remain separate. |

**Consistency rule applicable:** Yes for the registered printed-count relationship. Match the named DBP1 TG classification, placebo allocation and randomization time origin before comparing the baseline participant count with the displayed starting subgroup risk population. If these are distinct populations, a population rule is needed to relate the two printed values. No genotype-specific revision, different set or addition of participants is specified in the table, figure, caption or cited methods. This establishes the unresolved relationship between the two displayed populations. It does not establish that either risk count is necessarily the Cox model membership count.

**Calculation or logical comparison reproduced:** Yes. TG placebo difference is 59 − 57 = 2 participants. Main Table 1 placebo DBP1 categories total 82 + 57 + 9 = 148. The corresponding zero-year placebo risk counts total 82 + 59 + 9 = 150. Thus the category-sum consequence is 150 − 148 = 2, part of the same issue. Vitamin D category totals are 134 + 87 + 10 = 231 in both documents. The TT and GG placebo comparisons are respectively 82 versus 82 and 9 versus 9. No later contributor count, plotted curve height, event proportion or crude HR calculation is used.

**Display-precision interval check:** Participant counts are exact integers. Even allowing the permissive whole-unit half-rounding intervals, Table 1 TG 57 permits [56.5, 57.5), whereas eFigure 3Q TG 59 permits [58.5, 59.5); the intervals are disjoint. Restricting these intervals to integer participant counts leaves only 57 and 59. The 148/150 sums are calculated consequences of the exact displayed categories, not independently rounded population estimates. If continuous half-unit intervals were applied to all six summands without respecting their integer meaning, their sum ranges could overlap; that would not reconcile the matched TG pair or represent participant counts. Percentages and the Table 1 rounding footnote concern percentage displays and cannot convert one exact count into the other. No inferential estimate-versus-count identity is imposed.

**Necessary inputs available:** Yes for the mechanical count comparison: named genotype, allocated arm, table cells, zero-year time origin, risk-row values, matching adjacent categories and the accompanying HR/CI/P annotation are supplied and readable. These inputs suffice to reproduce the printed 57/59 discrepancy and its exact category-sum consequence.

**Exact missing inputs or definitions:** Participant-level DBP1 genotype availability and classification records; any genotype reassessment, imputation or changed inclusion rule between Table 1 and eFigure 3Q; the explicit relation between the curve's zero-year risk population and the Cox model's analytic membership; and the participant-level event/censor records and model specifications needed to recompute the HR/interaction test. The cited baseline 25(OH)D imputation procedure does not define a DBP1 genotype-population change. Their absence prevents selecting the intended count, identifying the cause or establishing any numerical effect on the HR; it does not prevent reproducing the printed count relationship.

**Source-grounded alternative interpretation:** The main characteristic table and subgroup curve may represent different genotype-available subsets, or one displayed count may require reconciliation with the analytic records. Different variable-specific genotype totals within Table 1 show that availability is not uniformly the whole randomized population, so a distinct subset is possible. However, the supplied context does not identify a 57-to-59 DBP1 TG placebo population change, and no alternative is established. The Table 1 percentages do not identify the Cox model membership or select which count should accompany the subgroup analysis.

**Direct observation versus inferred explanation:** Direct observations are the printed TG counts, matching TT/GG and vitamin D counts, named DBP1 subgroup/endpoint/time origin and exact sum arithmetic. The existence of additional genotyped participants, a changed classification, a transcription cause, distinct model memberships, a different HR or altered trial conclusions would be inferred explanations or consequences; none is established here. The associated model population is a question for human verification, not a fact derived from a risk row alone.

**Affected result or extracted value:** The extractable placebo DBP1 TG starting subgroup population accompanying the eFigure 3Q relapse-or-death HR 1.00 (95% CI 0.44–2.24), and the total implied by its displayed DBP1 placebo categories, can be taken as 57/148 from Table 1 or 59/150 from the supplement. The recheck does not assert a discrepancy in the HR, CI, P values or the whole-trial 417-person efficacy population.

**Determining recheck fact:** Direct reading reproduces placebo TG 57 in main Table 1 and 59 at zero years in eFigure 3Q, with agreeing TT/GG categories and no supplied contextual genotype-population reconciliation. No registered source value or location required transcription correction. These facts determine the single evidence state `reproduced`; it is an evidence-record fact and does not decide human adjudication.

**Exact remaining human question:** What placebo DBP1 TG population is intended for the eFigure 3Q starting risk row and associated relapse-or-death analysis, and what participant-selection or genotype-classification rule reconciles its 59 with Table 1's 57 and the corresponding 150/148 category sums? Which records establish the Cox model membership independently of the plotted initial risk count?

**Human verification steps:** Check the cited cells and zero-year risk rows, then consult genotype availability/classification and analytic membership records to determine the population rule. Establish the relationship to the model without choosing a replacement count from the display alone.

**Human adjudication fields:**
- **Validity:** __
- **Importance:** __
- **Action:** __
- **Initials:** __
- **Notes:** __

Completed scope: C001; evidence states: reproduced 1, reproduced_after_transcription_correction 0, not_reproduced 0. All affected/source-context locations were found. No source-page or tooling limitation. The named unsupplied genotype and model-membership records remain the human evidence boundary.
